Oncology Pulse: Latest Breakthroughs

The European Society for Medical Oncology Congress in Madrid shows strong survival gains from new cancer drugs.

“AstraZeneca's stomach cancer drug Sone-Ve doubled median survival to 10 months from 5 months in patients who had already tried at least two treatments.”

AstraZeneca Drug Shows Survival Gain

AstraZeneca's stomach cancer drug Sone-Ve doubled median survival to 10 months from 5 months in patients who had already tried at least two treatments.

Eli Lilly's Lung Cancer Drug

Eli Lilly's Olomorasib shrank tumors in 62% of 77 patients with KRAS G12C-mutated lung cancer.

Moderna and Merck's Cancer Vaccine

Moderna and Merck's personalized cancer vaccine cut recurrence risk by 42% when added to Keytruda.

Amgen's Lung Cancer Therapy

Amgen's Imdelltra extended median survival to 21.1 months versus 12.7 months for Imfinzi alone in small cell lung cancer.

Roche's KRAS Inhibitor

Roche's divarasib beat rival drugs from Amgen and Bristol-Myers Squibb in a head-to-head trial, nearly doubling response rates.

Summit's Biliary Cancer Trial

Summit's Ivonescimab combined with chemotherapy top Imfinzi plus chemotherapy in first-line biliary tract cancer in China.

AI Jitters and Oil Spikes

U.S. stocks dropped as AI spending jitters and surging oil prices triggered a sell-off, with Brent crude hitting $116.72.

Fed's Next Move

The Federal Reserve ends its two-day meeting Wednesday with 90% odds of holding rates steady, but inflation uncertainty may lead to a December rate hike.

Earnings Week Highlights

Visa, Alphabet, Sterling Infrastructure, EMCOR, Mastercard, Intel, Reddit, and Amazon report earnings this week with key metrics for investors.

TransDigm's Market Performance

TransDigm's stock is down 10% since March but shows strong sales growth and resilient cash flow despite market concerns.